Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Yahoo! Finance
clinical development to show benefit in patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and RCC Completed enrollment in the Phase 2b CORAL trial in IPF patients with chronic cough in February 2025 , with topline data expected in the second quarter of 2025 Announced positive outcome from sample size re-estimation in the Phase 2b CORAL trial, resulting in no change to study sample size Ended 2024 with $107.6 million in cash, cash equivalents and marketable securities, with expected cash runway into the second half of 2026 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn. March 18, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics to Participate in Upcoming April Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Trevi Therapeutics to Participate in Upcoming April Investor ConferencesPR Newswire
- Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $20.00 price target on the stock, up previously from $11.00.MarketBeat
- Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.50 price target on the stock.MarketBeat
- Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its price target lowered by analysts at Needham & Company LLC from $25.00 to $24.00. They now have a "buy" rating on the stock.MarketBeat
TRVI
Earnings
- 3/18/25 - Beat
TRVI
Sec Filings
- 3/26/25 - Form 4
- 3/25/25 - Form 4
- 3/21/25 - Form 144
- TRVI's page on the SEC website